poisar

Stocks · News reference

UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DGX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks.Com

    Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

    Zacks highlights strong stock performance from its various rating systems and portfolios. Oportun Financial gained 31% after a Zacks Rank upgrade, Uranium Royalty advanced 67.6% following an Outperform recommendation, and Amgen returned 25.1% over 12 weeks. The article discusses economic conditions marked by geopolitical tensions, rising energy costs, and resilient but cooling labor markets, while showcasing the historical outperformance of Zacks' investment methodologies.

    OPRTUROYAMGNURGNNGL
  2. John Ballard

    Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million

    Quest Diagnostics CEO J. E. Davis sold 10,000 shares worth $2.4 million on September 1, 2026, under a pre-planned Rule 10b5-1 trading arrangement. The sale represents 8% of his direct holdings, leaving him with $28.9 million in company stock. Analysts view this as a routine portfolio adjustment rather than a sign of concern about the company's fundamentals.

    DGX
  3. Bcc Research

    Global Pathology Services Market to Reach $307.9 Billion by 2030, Driven by Rising Cancer Incidence and AI-Enabled Diagnostic Innovation

    The global pathology services market is projected to grow from $212.8 billion in 2024 to $307.9 billion by 2030 at a 6.5% CAGR, driven by rising cancer incidence, digital pathology adoption, and molecular diagnostics expansion. North America leads with 41.2% market share, while AI-enabled platforms are delivering measurable ROI through cost savings and improved efficiency. Large reference laboratory operators are best positioned to capture outsourcing opportunities and scale molecular testing capabilities.

    DGXLHCRLSKHHYERRFY